More time to live: a drug combination extended median survival by over eight months in an advanced small cell lung cancer trial
A Phase 3 trial involving 563 patients found that tarlatamab plus durvalumab extended median survival to 21.1 months, compared with 12.7 months for durvalumab alone. The findings suggest a way to give some patients with extensive-stage small cell lung cancer longer lives after initial treatment, although serious side effects were more common.
Source: ynetnews.com
Read the original story →